INDIANAPOLIS (AP) - Drug maker Eli Lilly and Co. says it will take a $1.42 billion charge in the third quarter related to an investigation into marketing practices for the anti-psychotic Zyprexa.

The company says it is in advanced discussions to settle the investigation.

The investigation was led led by the U.S. Attorney's Office for the Eastern District of Pennsylvania. Lilly says the U.S. attorney's office launched its investigation in 2004.

The charge amounts to $1.29 per share.

Zyprexa has been Lilly's top-selling drug for years but also has been subject to reams of litigation. Earlier this month, Lilly announced a separate $62 million settlement with 32 states and Washington, D.C., over marketing practices.

(Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)